Life Sciences Company GeniPhys Adds CEO, Board Chair

Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowZionsville-based GeniPhys Inc. is adding to its leadership team. The company, which develops and commercializes collagen material technology developed at Purdue University, has selected Andrew Eibling as president and chief executive officer, while attorney Matthew Neff has been appointed chairman of the board.
The company says Eibling brings 35 years of leadership experience in the pharmaceutical, CRO and medtech space. Most recently, he was vice president of business development and alliance management at Ohio-based Enable Injections Inc.
“I am very excited to join GeniPhys and to help lead the continued development and commercialization of this technology,” Eibling said. “The work that Dr. Harbin and GeniPhys have done to develop a first-of-its-kind collagen polymer formulation and associated biofabrication methods will allow the custom design of collagen materials for a broad variety of tissue restoration and regeneration needs. Our first planned medical product, which represents a scaffold-forming liquid collagen, has the potential to accelerate healing and improve restoration of tissue cavities created by skin ulcers, traumatic injuries and surgical procedures, such as lumpectomies.”
Neff is executive director of Indianapolis-based Thompson Thrift, a developer of retail and multifamily housing developments. He previously served as president and CEO of AIT Laboratories Inc. in Texas.
“The GeniPhys platform presents a major opportunity to impact a broad range of patient needs due to its versatility and multiple formats,” Neff said. “Upon approval by the FDA, I believe these products will provide a significant advancement in tissue restoration and regeneration. I look forward to working with the GeniPhys team to help guide the direction of this company and technology.”
GeniPhys is an early-stage medical technology company focused on empowering tissue generation.